The Brave New World: Should we tread down the path to human germline editing?
By Sheetal Soni,
South African Journal of Bioethics and Law
| 06. 01. 2021
Gene-editing tools such as the CRISPR-Cas9 system create an opportunity for individuals to have their DNA edited for specific purposes. Somatic cell editing targets specific cells in an individual, and is aimed at providing a therapeutic mechanism to correct a genetic disease or condition. Germline editing refers to the editing of the DNA of embryos or gametes, which creates edits that are heritable. Following the announcement in 2018 that the Chinese scientist He Jiankui had proceeded to gene-edit human embryos, a moratorium on germline editing was quickly proposed. While an objective of the moratorium was to prevent clinical application of germline editing, it also served as an opportunity to engage in global debate on the issues inherent in gene editing. Heritable editing has become an ethically controversial topic in bioethics, and this article undertakes to provide a primer in the existing national and international legal framework for gene editing, as well as description of the prominent current views of heritable germline editing.
In his novel Brave New World, Aldous Huxley states that ‘We are not our own any more than...
Related Articles
Since the “CRISPR babies” scandal in 2018, no additional genetically modified babies are known to have been born. Now several techno-enthusiastic billionaires are setting up privately funded companies to genetically edit human embryos, with the explicit intention of creating genetically modified children.
Heritable genome editing remains prohibited by policies in the overwhelming majority of countries that have any relevant policy, and by a binding European treaty. Support for keeping it legally off limits is widespread, including among scientists...
By Ed Cara, Gizmodo | 06.22.2025
In late May, several scientific organizations, including the International Society for Cell and Gene Therapy (ISCT), banded together to call for a 10-year moratorium on using CRISPR and related technologies to pursue human heritable germline editing. The declaration also outlined...
By Isabel van Brugen, Newsweek | 06.05.2025
A U.S.-based biotech company has unveiled a new in vitro fertilization (IVF) option that allows parents to select embryos based on genetic markers tied to health and longevity.
DNA testing and analysis company Nucleus Genomics has announced the world's first...
By Jonathan D. Grinstein, PhD, Inside Precision Medicine | 06.03.2025
On Tuesday, 307 days after he was first admitted to Children’s Hospital of Philadelphia (CHOP), KJ Muldoon went home after being successfully treated with the first personalized CRISPR gene editing therapy. KJ, who was born with a serious and...